

PRESS RELEASE

Annual General Meeting of Shareholders in Active Biotech 29 March 2001

At Active Biotech AB's Annual General Meeting Sven Andréasson, Mats Arnhög, Maria Borelius, Svend Holst-Nielsen, Mats Pettersson, Peter Sjöstrand and Hugo Thelin were re-elected. Hugo Thelin will continue serving as Chairman of the Board.

Anders Williamsson and Håkan Åström, who have renounced a re-election due to other commitments, were thanked for their services by the Chairman of the Board, Hugo Thelin.

The President & CEO, Sven Andréasson's speech at the General Meeting is available for download (as well as the Annual Report) on our web-site www.activebiotech.com.

Lund 30 March 2001

Active Biotech AB (Publ)

Sven Andréasson
President & CEO

Active Biotech AB is a biotechnology company focusing on research and development of medicines and vaccines. Our expertise lies in the knowledge of the human immune defence system. We have a high-quality project portfolio and financial strength. The most important products and projects are medicines for multiple sclerosis (SAIK) and cancer (TTS), the SBL Cholera Vaccine, and Dukoral and ETEC vaccines against tourist diarrhoea. Active Biotech's turnover was MSEK 280 in 2000.

Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
e-mail info@activebiotech.com